Mina Tadrous, PharmD, PhD, professor of pharmacy at the University of Toronto, points to several other factors that weigh in injectables favor
Medical weight loss injections are considered safe forms of weight loss treatment with minimal side effects
Pulmonary Research Research has extended GHK-Cus applications into pulmonary tissue
These symptoms often appear during the first weeks of treatment or after dose increases
The dual Glucagon/GLP-1 agonist survodutide was also evaluated at different doses, with weekly subcutaneous injection in MASH patients without cirrhosis, with 39% of patients having T2DM
Additional work is also needed to evaluate the role of glycemic control (e.g., HbA1c), systemic inflammation and body composition as mediators of surgical outcomes